Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Other Operating Expenses: 2009-2025

Historic Other Operating Expenses for Amicus Therapeutics (FOLD) over the last 15 years, with Sep 2025 value amounting to $1.9 million.

  • Amicus Therapeutics' Other Operating Expenses fell 13.64% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 7.11%. This contributed to the annual value of $3.5 million for FY2024, which is 237.32% up from last year.
  • Per Amicus Therapeutics' latest filing, its Other Operating Expenses stood at $1.9 million for Q3 2025, which was down 47.27% from $3.6 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Other Operating Expenses high stood at $3.6 million for Q2 2025, and its period low was -$3.3 million during Q3 2021.
  • Over the past 3 years, Amicus Therapeutics' median Other Operating Expenses value was $2.0 million (recorded in 2024), while the average stood at $1.4 million.
  • In the last 5 years, Amicus Therapeutics' Other Operating Expenses crashed by 273.71% in 2021 and then skyrocketed by 958.17% in 2024.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' Other Operating Expenses stood at -$1.7 million in 2021, then grew by 8.65% to -$1.6 million in 2022, then spiked by 237.75% to $2.2 million in 2023, then declined by 6.46% to $2.0 million in 2024, then fell by 13.64% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $3.6 million for Q2 2025, and $1.8 million during Q1 2025.